🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Great lecture by Dr. Rupa Banerjee about environmental exposure and IBD - Unique opportunity for to study IBD as emerging disease - Many exposures linked to IBD, but evidence on how to incorporate into a practice still lacking Y-ECCO #ECCO2025

Several interesting pediatric IBD pearls from ECCO pedi UC update by Amit Assa and Eytan Wine at #ECCO2025 - High dose IFX induction in most pedi pts - Recommend proactive TDM w/ TNFi induction - Highlight huge problem with pedi IBD drug access- only 2 drugs approved!

In the midst of the exciting new/novel tx for UC, Appreciate #MilesParkes sharing still potential role of thiopurines for UC maintenance at #ECCO2025. Not everyone can afford biologics/advanced therapy. Akbar Waljee, MD MSc

By N. Ternette on HLA-DQA1*05 #ECCO2025 May explain heterogeneity of studies on risk of allele and TNFi immunogenicity - Subtype HLA-DQA*05:01 subtype associated with loss of response to IFX - Subtype HLA-DQA*05:05 subtype associated with loss of response to ADA

LOVE-CD study by Amsterdam UMC on dose escalation of VDZ #ECCO2025 - Primary non-response to VDZ induction - Dose intensification vs. standard dose VDZ - Dose intensification group NO difference @ 52weeks clinical/endo remission —> consider switch agent rather than escalate

Guselkumab UC SubQ induction #ASTRO trial #ECCO2025 - Effective in both bionaive and experienced - Clinical response delta ~30% over placebo @ 12 wk - Rates numerically similar to IV induction from QUASAR #ulcerativecolitis

Prof Reinisch presented companion RELIEVE UCCD- UC Induction #ECCO2025 - #Duvakitug TL1A Phase 2B - Primary outcome Clinical remission wk14 - 🔼 27% over placebo - Similar 🔼 bio experienced/naive - ?High placebo clinical response -52% vs. 81%/70% tx Sanofi Teva Pharmaceuticals

- SOR102: Novel oral dual acting local biologic Phase 1B study for UC - Fast potential onset of action in higher dose arm - Interesting PK- only detectable in serum in 1 pt - 6/12 pts developed anti-drug antibody? Low titer- clinical impact unclear #ECCO2025

GRAVITI SubQ induction of Guselkumab #ECCO2025 - Phase 3 GUS for Crohn’s - 12wk Clin Remission 🔼35% over plac - 12wk Endo response 🔼20% over plac - 48wk Clin Rem 🔼~39% over plac - 48wk Endo Res 🔼~38% over plac ⭐️Similar 12 and 48 wk data compared to IV induction

Prof Danese presenting LUCENT-URGE data #ECCO2025 - Open Label wk12 analysis or mirikizumab for #ulcerativecolitis - Looked at 3 new scales for urgency ⭐️ BU - severity ⭐️ BUF- frequency ⭐️ SDT- stool deferral time - All scales improved on Miri @ 12wk

Applaud Eli Lilly and Company for studying complexity of urgency in #ulcerativecolitis #Miri #ECCO2025 ⭐️ Interesting only weak to moderate correlation between the 3 different aspects of urgency ⭐️ Urgency is often the most isolating sx of UC, important for us to better understand

RESCUE- Prospective RCT of pts w/ secondary failure to ustekinumab in Crohn’s #ECCO2025 ⭐️ IV UST reinduction: 4 wk vs. 8 wk UST ⭐️ NO difference @ 48wk ⭐️ Both groups- Steroid free clinical remission <20% @ 48wk Limited value of pushing for q4wk UST ➡️ switch MOA?

Novel MoA Lusvertikimab IL-7 inhibitor for ulcerative colitis presented #ECCO2025 - Phase 2 RCT - Improved MMS over placebo @ 10wk - HEMI improvement in 32% @ 10wk (🔼 25% over placebo)

📢 Join us for the 24th Annual BCM GI & Liver Course! This event brings together experts, sharing latest innovations & advances in gastroenterology & liver disease. Open to physicians, NPs, PAs, nurses, fellows & trainees. Don't miss out! Register Here: cpd.education.bcm.edu/content/gi-liv…

Did you know Fasiha Kanwal’s attending was Maria T. Abreu? 😮 Or that Brijen Shah is an amusement park enthusiast? 🎢 We had a great time getting to know our newest board members today! Thank you to each of them for sharing about their work and interests.

After last year's SOLD OUT event, #IBDHorizons25 is once again teaming up with #TheOregonClinic and #DonaldLum for our City of 🌹Symposium on May 10 in PDX! Register bit.ly/43dAT3T Apply for a travel grant - deadline Monday, 4/14 bit.ly/3BRCAZj

I just boosted my IBD knowledge in today's by sitting near #krish_subramanian BCM Gastroenterology course

#Anemia is more than a Hb number, it affects #IBD pts QOL & outcomes 🗳️PreB2B Polls 🧵#Back2Basics Aimen Farooq Arooj Mian May 12 📌Convo Jason Hou May 19 🆓#CME👉🏽 bit.ly/MNIBD24-25 Support by educ grants AbbVie JanssenUS Takeda 📌Where r you in your🩺?

Big thanks to Scott D Lee, MD Ghassan Wahbeh, MD and #DonaldLum for the warm invite, and fun engaging program last weekend with IBDHorizons in Portland!

#MondayNightIBD Aline Charabaty, MD, FACG, AGAF AbbVie JanssenUS Takeda Sabina Ali,MD Joseph Sleiman, MD, FACP Tauseef Ali MD, FACG AGAF FACP Andrew Grossman MD Axel Dignass Dominik Bettenworth Fernando Gomollón Berkeley Limketkai Katie Dunleavy Haley Mertens 40M with ileocolonic #Crohns in clinical remission on UST, endo healing on last CLN 2 yrs ago. He says he feels fine. 🧪labs: Hb 10 g/dl, Ferritin 60 ng/ml #MondayNightIBD What would you at that visit?